NiRAN interfering drugs for SARS-CoV-2 mutant therapy
AssigneeAtea Pharmaceuticals, Inc.
InventorsJean-Pierre Sommadossi, Kai Lin, Adel Moussa, Bruno Canard, Ashleigh Shannon
Life of this patent
Estimating the term…
Abstract
Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12). The invention establishes for the first time herein the foundational discovery of the mechanism of action of the NiRAN-domain, and how it can be used in pharmaceutical therapy against SARS-CoV infection, including a SARS-CoV-2 infection, or exposure.
Claims28
A method for the treatment of an infection with a remdesivir-resistant strain of SARS-COV-2 virus in a human in need thereof, comprising administering an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, wherein:
- R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or aryl-C1-4alkyl;
- R2 is hydrogen or C1-6alkyl;
- R3a and R3b are independently selected from hydrogen, C1-6alkyl, and C3-7cycloalkyl;
- and
- R4 is hydrogen, C1-6alkyl, C1-6haloalkyl, C3-7cycloalkyl, or aryl-C1-4alkyl.
A method for the treatment of an infection with a remdesivir-resistant strain of SARS-COV-2 virus in a human in need thereof, comprising administering an effective amount of Compound 1:
- or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.